https://pharmadevicenews.com/can-johnson-johnsons-oral-icotyde-compete-with-biologics-in-psoriatic-arthritis/ PharmaDeviceNews en 2026-11-09T07:18:25+00:00 Can Johnson & Johnson’s oral Icotyde compete with biologics in psoriatic arthritis? American College of Rheumatology, Bristol Myers Squibb, deucravacitinib, guselkumab, ICONIC-PsA 1, icotrokinra, ICOTYDE, Johnson & Johnson, Protagonist Therapeutics, Sotyktu, TREMFYA https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/cesalatamig-controlled-disease-in-90-at-its-chosen-dose-is-oncoc4-ready-for-a-pivotal-nsclc-test/ PharmaDeviceNews en 2026-11-09T07:06:08+00:00 Cesalatamig controlled disease in 90% at its chosen dose. Is OncoC4 ready for a pivotal NSCLC test? AI-081, BiPAVE-001, cesalatamig, OncoC4, Society for Immunotherapy of Cancer, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-19-2026-08_01_16-PM-e1789828314671.webp https://pharmadevicenews.com/novartis-lowered-a-major-inherited-heart-risk-marker-by-78-why-did-patients-not-benefit/ PharmaDeviceNews en 2026-11-08T16:52:26+00:00 Novartis lowered a major inherited heart-risk marker by 78%. Why did patients not benefit? American Heart Association, Amgen, Eli Lilly and Company, Ionis Pharmaceuticals, lepodisiran, Lp(a)HORIZON, Novartis, olpasiran, pelacarsen https://pharmadevicenews.com/wp-content/uploads/2026/05/Ribos-RBD1119-Phase-2-filing-puts-siRNA-antithrombotics-into-sharper-cardiovascular-focus-e1779979227353.webp https://pharmadevicenews.com/rybrevant-faspro-shrank-tumours-in-42-of-heavily-treated-head-and-neck-cancer-patients-can-phase-3-confirm-the-benefit/ PharmaDeviceNews en 2026-11-08T16:46:31+00:00 Rybrevant Faspro shrank tumours in 42% of heavily treated head and neck cancer patients. Can Phase 3 confirm the benefit? amivantamab, Halozyme Therapeutics, Janssen Biotech, Johnson & Johnson, OrigAMI-4, OrigAMI-5, RYBREVANT FASPRO, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/07/Natera-expands-Signatera-evidence-with-head-to-head-Merkel-cell-carcinoma-study-e1784720429133.webp https://pharmadevicenews.com/can-samsung-bioepis-challenge-keytruda-after-its-u-s-patent-cliff-begins-in-2028/ PharmaDeviceNews en 2026-11-07T15:32:42+00:00 Can Samsung Bioepis challenge Keytruda after its U.S. patent cliff begins in 2028? Formycon, FYB206, Keytruda, Keytruda Qlex, Merck & Co., pembrolizumab, Samsung Bioepis, Samsung Epis Holdings, SB27, Society for Immunotherapy of Cancer, Zydus Lifesciences https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-17-2026-09_15_56-AM-e1789616803290.webp https://pharmadevicenews.com/siemens-healthineers-carves-out-diagnostics-business-as-olyrian-after-q4-margin-falls-to-5-4/ PharmaDeviceNews en 2026-11-07T15:25:18+00:00 Siemens Healthineers carves out diagnostics business as Olyrian after Q4 margin falls to 5.4% Olyrian Diagnostics, Siemens AG, Siemens Healthineers https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Diagnostics-generic.webp https://pharmadevicenews.com/johnson-johnson-tests-rybrevant-beyond-nsclc-as-origami-5-phase-3-trial-advances/ PharmaDeviceNews en 2026-11-07T15:17:14+00:00 Johnson & Johnson tests Rybrevant beyond NSCLC as OrigAMI-5 Phase 3 trial advances amivantamab, Janssen Biotech, Johnson & Johnson, OrigAMI-4, OrigAMI-5, RYBREVANT FASPRO, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/01/ovarian-cancer-research-and-drug-development.webp https://pharmadevicenews.com/immunocore-saw-70-of-first-line-patients-alive-at-two-years-can-two-t-cell-engagers-really-beat-kimmtrak-alone/ PharmaDeviceNews en 2026-11-07T14:46:57+00:00 Immunocore saw 70% of first-line patients alive at two years. Can two T-cell engagers really beat KIMMTRAK alone? Brenetafusp, DUET-UVEAL, gp100, IMC-F106C-101, Immunocore Holdings plc, KIMMTRAK, PRAME, Society for Immunotherapy of Cancer, tebentafusp https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-research-lab.webp https://pharmadevicenews.com/agenus-botbal-shows-long-term-survival-in-refractory-mss-colorectal-cancer/ PharmaDeviceNews en 2026-11-07T14:39:03+00:00 Agenus BOT+BAL shows long-term survival in refractory MSS colorectal cancer Agenus, balstilimab, BOT+BAL, botensilimab, C-800-01, ROBBIN https://pharmadevicenews.com/wp-content/uploads/2026/06/Genentechs-Tecentriq-review-raises-hopes-for-a-new-adjuvant-colon-cancer-standard-e1781193946367.webp https://pharmadevicenews.com/bristol-myers-squibb-camzyos-franchise-reaches-1-15bn-as-pediatric-evidence-expands/ PharmaDeviceNews en 2026-11-07T14:35:38+00:00 Bristol Myers Squibb Camzyos franchise reaches $1.15bn as pediatric evidence expands Bristol Myers Squibb, Camzyos, Cytokinetics, Mavacamten, Myqorzo, SCOUT-HCM, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/07/Cardiologist-review-e1785437553884.webp https://pharmadevicenews.com/metavias-tiny-phase-1-obesity-study-just-posted-13-5-weight-loss-and-a-68-liver-fat-reduction-how-much-can-investors-trust-yet/ PharmaDeviceNews en 2026-11-07T14:20:16+00:00 MetaVia’s tiny Phase 1 obesity study just posted 13.5% weight loss and a 68% liver-fat reduction. How much can investors trust yet? DA-1726, MetaVia, Precision Liver Symposium https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Clinical-Trials.webp https://pharmadevicenews.com/onkos-can-put-its-antibacterial-coating-on-more-implants-the-fda-claim-stops-well-short-of-preventing-infection/ PharmaDeviceNews en 2026-11-07T14:16:54+00:00 Onkos can put its antibacterial coating on more implants. The FDA claim stops well short of preventing infection ELEOS Limb Salvage System, NanoCept, NanoCept Innovation Center, Onkos Surgical, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Medical-Devices.webp https://pharmadevicenews.com/can-moderna-sustain-its-comeback-beyond-covid-vaccines-and-intismeran/ PharmaDeviceNews en 2026-11-07T14:12:43+00:00 Can Moderna sustain its comeback beyond COVID vaccines and intismeran? intismeran autogene, Merck & Co., MFLUSIVA, mNEXSPIKE, Moderna, mRESVIA, Spikevax https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-19-2026-07_56_50-PM-e1789828044512.webp https://pharmadevicenews.com/immunocore-reports-70-two-year-survival-with-dual-t-cell-engager-combination-in-uveal-melanoma/ PharmaDeviceNews en 2026-11-07T13:42:16+00:00 Immunocore reports 70% two-year survival with dual T-cell engager combination in uveal melanoma Brenetafusp, DUET-UVEAL, Immunocore Holdings, KIMMTRAK, Society for Immunotherapy of Cancer, tebentafusp https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/what-the-zolgensma-tumour-reports-mean-for-novartis-and-aav-gene-therapy-safety/ PharmaDeviceNews en 2026-11-07T13:29:29+00:00 What the Zolgensma tumour reports mean for Novartis and AAV gene therapy safety GLI1, Itvisma, Novartis AG, onasemnogene abeparvovec, U.S. Food and Drug Administration, Zolgensma https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Cancer-generic.webp